Completed PHASE2 INTERVENTIONAL 2-arm NCT02153671

Immunogenicity of H5N1 Vaccine Following H5N2

Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects

Sponsor: Institute of Experimental Medicine, Russia

Conditions Influenza Vaccine

Interventions A(H5N1) inactivated influenza vaccine (IIV) A(H5N2) live attenuated influenza vaccine (LAIV)

Updated 9 times since 2017 Last updated: Feb 14, 2019 Started: May 31, 2014 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Influenza Vaccine, this trial is completed. The trial is conducted by Institute of Experimental Medicine, Russia and has accumulated 9 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Mar 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Experimental Medicine, Russia
PATH
Research Institute of Influenza, Russia

Data source: PATH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Petersburg, Russia